Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Asan Medical Center · University of Ulsan · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
756
total citations
- FWCI
- 71.55
- Percentile
- 100%
- References
- 31
Citations per year
Authors
25- YKYoon‐Koo Kang
Asan Medical Center, University of Ulsan, Ulsan College
- LCLi‐Tzong Chen
Kaohsiung Medical University, National Cheng Kung University Hospital, National Health Research Institutes, Kaohsiung Medical University Chung-Ho Memorial Hospital
- MRMin‐Hee Ryu
Ulsan College, University of Ulsan, Asan Medical Center
- DODo‐Youn Oh
Seoul National University, Seoul National University Hospital
- SCSang Cheul Oh
Korea University, Dong-A University Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Capecitabine
- Oxaliplatin
- Internal medicine
- Chemotherapy
- Placebo
- Gastroenterology
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.